Program Leakage: A Closed-Loop Framework for Recovery and Prevention

A note about language, and why it matters.

The vocabulary around program integrity in patient support has historically borrowed from fraud investigation. "Fraud, waste, and abuse" (FWA) is the shorthand carried over from Medicare/Medicaid integrity programs. "Fraud detection" is the label most vendors still use on their analytics packages.

That vocabulary creates two problems. The first is legal: manufacturer patient support programs are commercial contracts, not government benefits. Accusing a pharmacy, prescriber, or patient of "fraud" based on statistical pattern detection is a serious claim with evidentiary requirements most programs can't meet. The second is operational: the fraud framing implies an adversarial posture toward pharmacies and providers that a manufacturer doesn't actually want — because those same pharmacies and providers are the distribution pathway for the drug.

There's a better vocabulary. It's more precise, more defensible, and more aligned with what the work actually is.

The words that work

• Anomaly identification — not fraud detection. An anomaly is a statistical deviation from the expected pattern of claim activity. That's an empirical finding. "Fraud" is a legal conclusion.

• Program integrity monitoring — not FWA monitoring. Program integrity is the set of processes that ensure manufacturer funds are being used in accordance with program terms. Forward-looking posture, not backward-looking accusation.

• Fund protection — not loss recovery. The goal is to prevent confirmed non-compliant claims from leaving the program in the first place, not to chase funds that have already been disbursed.

• Pharmacy oversight, claim review, and audit — not investigation. These are standard commercial activities. Investigation implies wrongdoing before the evidence supports it.

This isn't just semantics. The vocabulary shapes what the infrastructure actually does — and what you can defensibly do with the output.

The operational framework

The work of program integrity breaks into three continuous phases, each of which produces something the manufacturer can measure.

• Surface. Statistical and AI-powered analysis identifies claim patterns that deviate from expected norms at the prescriber, pharmacy, patient, and NDC levels. This is an anomaly signal, not a fraud declaration.

• Protect. Confirmed anomalies result in controlled financial corrections — reversing or holding disbursements through the standard adjudication pipeline, not through a separate adversarial process.

• Harden. Confirmed patterns become enforceable program rules that prevent the same tactic from recurring. The program gets tighter every quarter.

Notice what's missing from the framework: fraud proceedings, investigations, law enforcement referrals. The work is commercial, not investigative. The tools are billing corrections, not prosecution.

What to ask when you evaluate this capability

When you're evaluating a program integrity capability from a vendor, the questions worth asking aren't about fraud-detection accuracy. They're about:

• Vocabulary. Does the vendor use the language of anomaly identification and program integrity — or the language of fraud? The vocabulary tells you how defensible their output actually is.

• Action pathway. What happens between "anomaly identified" and "correction made"? If the answer involves you building the pathway yourself, the capability isn't complete.

• Integration with adjudication. Does the anomaly identification system live inside the same platform that processes your claims — or alongside it? Alongside-the-platform means funds have left by the time the signal fires.

• Rule conversion. When a pattern is confirmed, how does it become an enforceable program rule? Through a code change? A support ticket? Or a configuration change?

Answers to those four questions will tell you more than any fraud-detection accuracy percentage.

The broader point

Program integrity is one of the most important capabilities in modern patient support — and one of the most commonly mis-positioned. The vendors that pitch it as fraud detection are selling a posture. What actually protects manufacturer economics is continuous fund protection integrated into the adjudication workflow, with a commercial — not adversarial — response framework.

Get the vocabulary right and the work becomes clearer. Get the work right and the economics follow.